Get the Stockscreener App
205.99
1.40%
-2.93
After Hours:
210.74
4.75
+2.31%
Biogen Inc stock is traded at $205.99, with a volume of 1.15M.
It is down -1.40% in the last 24 hours and up +3.68% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$208.92
Open:
$208.6
24h Volume:
1.15M
Relative Volume:
0.92
Market Cap:
$30.41B
Revenue:
$9.60B
Net Income/Loss:
$1.37B
P/E Ratio:
22.11
EPS:
9.3182
Net Cash Flow:
$2.32B
1W Performance:
+3.43%
1M Performance:
+3.68%
6M Performance:
+25.28%
1Y Performance:
+60.07%
1-Day Range:
$203.40
$215.79
1-Week Range:
$186.03
$215.79
52-Week Range:
$121.05
$219.72
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
205.99 | 30.84B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,179.11 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.04 | 601.73B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.49 | 449.45B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.50 | 315.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.76 | 291.42B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Upgrade | UBS | Neutral → Buy |
| Apr-20-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-14-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-09-26 | Reiterated | H.C. Wainwright | Buy |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen stock trades steady as Alzheimer’s revenue and pipeline shape valuation - ad-hoc-news.de
Biogen’s mixed Alzheimer’s data; Two new startups launch; and more - Endpoints News
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter? - TradingView
Biogen Taps Biopharmaceutical Veteran as Chief Legal Officer - Bloomberg Law News
Biogen moves forward with Alzheimer's drug candidate following phase 2 study - medwatch.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Shareholders to Connect - The National Law Review
Rx Rundown: Biogen, Neko Health, Roche and more - Medical Marketing and Media
Is Biogen (BIIB) a Buy, Hold, or Sell Right Now - Kavout | AI
Biogen shares slide as diranersen data raise dosing question - The Pharma Letter
Roche/ Biogen kidney drug granted FDA priority review for label expansion - Seeking Alpha
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data - Yahoo Finance
Biogen names Michael Parini as chief legal officer - Investing.com
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
Biogen names Michael Parini as chief legal officer By Investing.com - Investing.com Canada
Biogen Appoints Michael J. Parini as Chief Legal Officer - Biogen
Press Release: Biogen Appoints Michael J. Parini as Chief Legal Officer - Moomoo
Form S-1 Biogen Inc For: 15 July By Investing.com - Investing.com Nigeria
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data - Clinical Trials Arena
Tau In The Clinic, Again - Seeking Alpha
Biogen (BIIB) Is Down 6.7% After At-Home LEQEMBI Launch And New Alzheimer’s DataHas The Bull Case Changed? - simplywall.st
Anti-Tau Agent Diranersen Slows Cognitive Decline Across Multiple Endpoints in Phase 2 CELIA Trial, Biogen to Advance to Phase 3 - NeurologyLive
Biogen stock holds steady as Alzheimer portfolio and pipeline shape the long-term story - Ad-hoc-news.de
Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact - Yahoo Finance
Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026Slideshow - Seeking Alpha
Biogen Inc (BIIB) Shares Fall 8.2% -- What GF Score of 74 Tells Investors - GuruFocus
Biogen Inc.'s Stock Price Plummets to $191.95, Recording a Sharp 8.17% DropThe Latest Market Update - Smartkarma
Biogen (BIIB) Alzheimer’s Association International Conference (AAIC Meeting) 2026 summary - Quartr
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss - Yahoo Finance
BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study - Stocktwits
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches - Los Angeles Times
Biogen (BIIB) Shares Face Scrutiny After CELIA Study Results - GuruFocus
Biogen (BIIB) Receives Mixed Feedback on CELIA Study Data - GuruFocus
Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem - Barron's
Biogen at aaic 2026: tau drug advances despite mixed trial readout - Investing.com
IBM, Goldman Sachs, SK Hynix, Micron, CrowdStrike, Biogen, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed - Reuters
Biogen (BIIB) Reports Mixed Results on Alzheimer's Drug Diraners - GuruFocus
Biogen Stock Falls After Lackluster Trial Data for Alzheimer's Drug Targeting Tau - Briefs Finance
Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi - Yahoo Finance
Biogen Inc at Alzheimer's Association International Conference (AAIC) Transcript - GuruFocus
Why Is Biogen Stock Falling Tuesday? - Benzinga
Eisai, Biogen report real-world Alzheimer’s drug study results - Investing.com
Biogen tumbles 8.7% as breakthrough Alzheimer’s data is clouded by dosing paradox - Investing.com South Africa
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment - Biogen
Biogen drops after data for novel Alzheimer’s drug (BIIB:NASDAQ) - Seeking Alpha
Nearly 87% of Alzheimer's Patients Chose to Stay on LEQEMBI - Stock Titan
Biogen Drops 7.7% After Morgan Stanley Maintains Equal-Weight - AlphaStreet
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):